HC-1119 Adjuvant Treatment for Hospitalized COVID-19 Patients
NCT04986176 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 602
Last updated 2022-02-18
Summary
The primary purpose of this study is to evaluate the efficacy of HC-1119 as an adjuvant treatment for hospitalized COVID-19 male and female patients.
Conditions
- COVID-19 Respiratory Infection
Interventions
- DRUG
-
HC-1119
oral
- DRUG
-
oral
Sponsors & Collaborators
-
Hinova Pharmaceuticals Inc.
collaborator INDUSTRY -
Applied Biology, Inc.
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-04-15
- Primary Completion
- 2022-12-31
- Completion
- 2022-12-31
More Related Trials
-
A Study to Assess the Efficacy of HH-120 Nasal Spray for Prevention of SARS-CoV-2 Infection in Adult Close Contacts of Individuals Infected With SARS-CoV-2
NCT05765279 ·Status: COMPLETED ·Phase: NA
-
A Study to Assess the Safety, Tolerability and Preliminary Efficacy of HH-120 for the Treatment of COVID-19
NCT06039163 ·Status: COMPLETED ·Phase: PHASE1
-
Atovaquone for Treatment of COVID-19
NCT04456153 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)
NCT04439071 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
NCT05047601 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)
NCT04405739 ·Status: COMPLETED ·Phase: PHASE2
-
HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2
NCT05787418 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)
NCT04575584 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients
NCT04345692 ·Status: TERMINATED ·Phase: PHASE3
-
Study to AntagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19
NCT04634799 ·Status: SUSPENDED ·Phase: PHASE1/PHASE2
-
An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19
NCT04527133 ·Status: UNKNOWN ·Phase: NA
-
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
NCT06667700 ·Status: RECRUITING ·Phase: PHASE3
-
Intranasal Heparin Treatment to Reduce Transmission Among Household Contacts of COVID 19 Positive Adults and Children
NCT05204550 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
NCT05261139 ·Status: RECRUITING ·Phase: PHASE3
-
Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019)
NCT04554992 ·Status: COMPLETED ·Phase: PHASE1
-
An Observational Cohort Trial of Outcomes and Antibody Responses Following Treatment With COVID19 Convalescent Plasma in Hospitalized COVID-19 Patients
NCT04471051 ·Status: COMPLETED
-
First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.
NCT04535167 ·Status: COMPLETED ·Phase: PHASE1
-
Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)
NCT04328961 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Intranasal INNA-051 for Prevention of COVID-19 in Adults
NCT05118763 ·Status: WITHDRAWN ·Phase: PHASE2
-
Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19
NCT04405570 ·Status: COMPLETED ·Phase: PHASE2
-
Pyridostigmine in Severe SARS-CoV-2 Infection
NCT04343963 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19
NCT04379492 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation
NCT04539262 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of HH-120 Nasal Spray in Close Contacts of Those Diagnosed With COVID-19
NCT05747677 ·Status: COMPLETED ·Phase: NA
-
Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)
NCT04547140 ·Status: TERMINATED ·Phase: PHASE2